Zydus Lifesciences Ltd

₹ 416 1.06%
02 Dec - close price
About

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Key Points

One of the top five pharmaceutical companies in India.[1]

  • Market Cap 42,057 Cr.
  • Current Price 416
  • High / Low 487 / 319
  • Stock P/E 21.4
  • Book Value 165
  • Dividend Yield 0.60 %
  • ROCE 14.7 %
  • ROE 14.7 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company has been maintaining a healthy dividend payout of 17.6%

Cons

  • Stock is trading at 2.52 times its book value
  • The company has delivered a poor sales growth of 10.2% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
3,367 3,638 3,752 3,515 3,659 3,633 3,670 4,025 3,760 3,640 3,864 4,073 4,135
2,731 2,940 2,961 2,724 2,845 2,866 2,821 3,092 2,860 2,888 3,146 3,240 3,319
Operating Profit 636 698 791 790 814 766 850 933 900 752 718 833 815
OPM % 19% 19% 21% 22% 22% 21% 23% 23% 24% 21% 19% 20% 20%
-251 14 -8 38 -70 54 -125 54 2,443 54 64 55 50
Interest 90 80 82 68 45 27 23 27 30 31 38 34 35
Depreciation 172 174 178 173 175 176 175 183 177 177 185 181 182
Profit before tax 122 457 522 588 524 617 526 777 3,135 598 558 673 648
Tax % 32% 20% 21% 20% 19% 17% -39% 18% 4% 18% 20% 18% 21%
Net Profit 94 371 414 487 435 528 735 642 3,012 511 453 576 526
EPS in Rs 1.05 3.65 3.83 4.43 4.62 5.15 6.63 5.74 29.33 4.89 3.88 5.06 5.16
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
4,631 5,263 6,358 7,224 8,651 9,427 9,376 11,905 13,166 14,253 14,404 15,265 15,711
3,602 4,177 5,228 6,021 6,896 7,095 7,474 9,074 10,174 11,455 11,013 11,923 12,593
Operating Profit 1,028 1,086 1,130 1,203 1,756 2,332 1,902 2,831 2,991 2,798 3,391 3,342 3,118
OPM % 22% 21% 18% 17% 20% 25% 20% 24% 23% 20% 24% 22% 20%
11 49 32 30 45 112 127 111 183 -264 -231 2,581 223
Interest 70 183 169 90 68 53 45 91 194 342 159 127 139
Depreciation 127 158 185 201 287 292 373 539 599 696 670 713 725
Profit before tax 842 794 809 942 1,446 2,099 1,612 2,312 2,382 1,495 2,331 5,084 2,477
Tax % 13% 14% 15% 11% 18% 8% 8% 24% 22% 21% 8% 10%
Net Profit 736 681 690 836 1,188 1,964 1,517 1,810 1,899 1,204 2,185 4,618 2,066
EPS in Rs 6.95 6.37 6.38 7.85 11.24 18.89 14.53 17.35 18.06 11.49 20.84 43.83 18.99
Dividend Payout % 18% 24% 24% 23% 21% 17% 22% 20% 19% 30% 17% 6%
Compounded Sales Growth
10 Years: 11%
5 Years: 10%
3 Years: 5%
TTM: 4%
Compounded Profit Growth
10 Years: 13%
5 Years: 8%
3 Years: 7%
TTM: -22%
Stock Price CAGR
10 Years: 9%
5 Years: 0%
3 Years: 18%
1 Year: -10%
Return on Equity
10 Years: 21%
5 Years: 18%
3 Years: 16%
Last Year: 15%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
102 102 102 102 102 102 102 102 102 102 102 102 101
Reserves 2,069 2,484 2,842 3,337 4,149 5,597 6,858 8,642 10,284 10,273 12,890 16,897 16,564
1,092 2,289 2,918 2,700 2,651 2,442 5,207 5,407 7,899 7,986 4,608 4,221 2,446
1,348 1,548 1,512 1,847 2,144 2,208 2,937 3,632 4,945 5,115 6,165 6,421 6,518
Total Liabilities 4,611 6,423 7,374 7,986 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,629
1,833 2,857 3,026 3,124 3,352 3,748 5,755 6,483 12,164 12,230 12,133 12,253 12,271
CWIP 431 484 736 892 798 951 1,543 1,527 837 742 783 661 958
Investments 21 24 114 87 154 416 435 746 674 765 830 3,288 1,087
2,326 3,058 3,498 3,885 4,743 5,235 7,371 9,028 9,556 9,740 10,019 11,439 11,314
Total Assets 4,611 6,423 7,374 7,986 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,629

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
683 511 603 903 994 1,894 1,312 919 1,282 2,932 3,294 2,104
-466 -1,200 -682 -438 -465 -860 -2,872 -974 -3,977 -1,004 -837 1,137
-172 860 286 -529 -351 -935 2,316 52 1,885 -1,528 -2,548 -868
Net Cash Flow 44 171 207 -64 178 99 756 -3 -811 399 -90 2,373

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 60 64 55 57 67 68 89 98 110 94 79 80
Inventory Days 201 234 191 184 175 158 193 211 208 207 246 245
Days Payable 141 117 103 123 125 154 165 167 149 152 168 141
Cash Conversion Cycle 120 181 142 119 118 71 116 142 169 149 158 184
Working Capital Days 53 58 63 46 56 46 62 95 99 79 95 111
ROCE % 31% 24% 18% 18% 23% 29% 16% 18% 15% 12% 15% 15%

Shareholding Pattern

Numbers in percentages

Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
74.88 74.88 74.88 74.88 74.88 74.88 74.88 74.88 74.88 74.88 74.88 74.98
4.58 4.41 4.56 4.38 5.24 5.23 4.65 4.11 3.79 2.53 2.86 2.61
12.62 12.90 12.59 12.50 11.72 11.30 10.50 11.25 11.80 12.83 11.94 12.86
0.13 0.14 0.19 0.19 0.19 0.19 0.07 0.07 0.07 0.08 0.08 0.07
7.80 7.67 7.78 8.05 7.97 8.40 9.90 9.69 9.46 9.69 10.24 9.47

* The XBRL reporting format changed from Sep'2022 onwards. The new format added details about banks and foreign portfolio investors. These were not available earlier.
The sudden increase in FII or DII might be because of these changes.

Please click on the line-items to see the names of individual entities.

Documents

Concalls